الصفحة 83
الصفحة 83
Drug safety evaluation : Methods and protocols
Focuses on the most recent advances in the field of drug safety evaluation. Divided into seven parts, chapters detail specific aspects related to the experimental design of preclinical studies conducted to support the safety of pediatric and combination drugs, necropsy and histopathology evaluation, mass spectrometry imaging, genetic toxicology protocols including the Pig-a mutation assay, safety pharmacology methods such as automatization of patch-clamp procedures, target safety assessment for investigative toxicology, screening assays for developmental toxicology, and methods to characterize novel translational safety biomarkers like microRNAs. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting to avoid known pitfalls.
Drug safety evaluation
Presents an all-inclusive practical guide for those who are responsible for developing new drugs and ensuring the safety of an ever-expanding spectrum of therapeutics. This book helps readers understand how the safety of these products are evaluated for use. Extensively revised to reflect up-to-date information, this edition includes changes to the scope of products (vaccines, small synthetic, large protein moieties, cells and tissues), harmonized global and national regulatory requirements, the therapeutic development process, and available technologies to identify and evaluate the relevance of potential patient risks
Drug residues in animal products
The use of veterinary drugs in food-producing animals has the potential to generate residues in animal derived products (meat, milk, eggs and honey) and poses a health hazard to the consumer. There are many factors influencing the occurrence of residues in animal products such as drug's properties and their pharmacokinetic characteristics, physicochemical or biological processes of animals and their products. The most likely reason for drug residues might be due to improper drug usage and failure to keep the withdrawal period...
Drug repurposing and computational drug discovery strategies and advances
Defined as identifying new pharmacological indications from old, existing, failed, investigational, already marketed, or FDA-approved drugs and prodrugs, and applying these new uses in the treatment of diseases other than the drug’s original intended therapeutic use. The application of computational techniques in discovery research not only helps in the development of drugs from leads or existing drug molecules but can also be useful for the repurposing of existing drug candidates.
Drug repurposing : A new fashion for a new hope
The repurposing of drugs is becoming increasingly attractive as it avoids the long process and cost implications associated with bringing a novel drug to market i.e., drug repurposing is cost effective and time saving. This study will discuss the repositioning of several drugs that belong to different pharmaceutical classifications such as antimicrobials (itraconazole and fluoroquinolones), anti-diabetic agents (metformin and sodium glucose co-transporter 2 inhibitors), cardiovascular drugs (β-blockers and digoxin), anticonvulsants (topiramate), immunosuppressants (sirolimus), non-steroidal anti-inflammatory drugs (NSAIDs e.g., COX inhibitors), and cholesterol lowering drugs (statins).
Drug Metabolism: Current Concepts
The user-friendly text focuses on concepts rather than extraneous details and is supported by many illustrated examples of biotransformations as well as frequent references to current critical reviews and articles highlighting the nature of research objectives in this vibrant area of medicinal development.
Drug Metabolism, Pharmacokinetics and Bioanalysis
Drug metabolism/pharmacokinetics and drug interaction studies have been extensively carried out in order to secure the druggability and safety of new chemical entities throughout the development of new drugs. Recently, drug metabolism and transport by phase II drug metabolizing enzymes and drug transporters, respectively, as well as phase I drug metabolizing enzymes, have been studied. A combination of biochemical advances in the function and regulation of drug metabolizing enzymes and automated analytical technologies are revolutionizing drug metabolism research. There are also potential drug-drug interactions with co-administered drugs due to inhibition and/or induction of drug metabolic enzymes and drug transporters.
Drug interactions in infectious diseases : Mechanisms and models of drug interactions
Provides a comprehensive review of basic clinical pharmacology with a focus on metabolism and transporter-mediated drug interactions. The chapters address materials that cannot be retrieved easily in the medical literature, including materials focused on the complex interrelationship of acute infection, inflammation, and the risk of drug interactions in the Drug-Cytokine chapter. The Food-Drug and Herb-Drug interactions chapters remain definitive resources. A new chapter on in vitro modeling of drug interactions is included along with updates on design and data analysis of clinical drug interaction studies. Authoritative discussion of models for regulatory decision-making on drug-drug interactions provides the necessary framework to aid antimicrobial drug development. This concise review of the mechanisms and models of drug interactions provides important insights to health care practitioners as well as scientists in drug development
Drug interactions in infectious diseases : Antimicrobial drug interactions
Delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
Drug disposition and pharmacokinetics : Principles and applications for medicine, toxicology and biotechnology
Delivers an authoritative and comprehensive discussion of the fate of drug molecules in the body, as well as its implications for pharmacological and clinical effects. The text offers a unique and balanced approach that combines discussion of the specific physical and biological factors affecting the absorption, distribution, metabolism, and excretion of drugs, with mathematical assessments of plasma and body fluid concentrations. The book assumes little prior knowledge and is an ideal reference for practicing professionals in industry as well as researchers and academics.
Drug discovery with privileged building Blocks : Tactics in medicinal chemistry
Drug Discovery with Privileged Building Blocks traces back PharmaBlock’s founding philosophy of designing privileged building blocks. High-quality building blocks are crucial not only to biological activities of different molecules but also to ADMET properties, which eventually will impact the success rate of drug discovery projects. A thorough study of how building blocks perform in drug molecules and a regular analysis of new building block structures in the latest researches have proven to be a fruitful strategy to generate novel building blocks. Using this strategy, PharmaBlock has supplied the drug industry with a great number of building blocks, which are increasingly being adopted by drug hunters, and these are identified in this book.
Drug discovery and GBCR – Related CNS Disorders
Neurodegenerative diseases are a large group of neurological disorders with diverse etiological and pathological phenomena. However, current therapeutics rely mostly on symptomatic relief while failing to target the underlying disease pathobiology. G-protein-coupled receptors (GPCRs) are one of the most frequently targeted receptors for developing novel therapeutics for central nervous system (CNS) disorders. Many currently available antipsychotic therapeutics also act as either antagonists or agonists of different GPCRs. Therefore, GPCR-based drug development is spreading widely to regulate neurodegeneration and associated cognitive deficits through the modulation of canonical and noncanonical signals.
Drug Discovery and Evaluation : Safety and Pharmacokinetic Assays
This book is a landmark in the continuously changing world of drugs. It is essential reading for scientists and managers in the pharmaceutical industry who are involved in drug finding, drug development and decision making in the development process.
Drug Discovery and Evaluation
The 3rd edition of this successful reference book contains an updated selection of the most frequently used assays for reliably detecting the pharmacological effects of potential drugs. Effects covered include cardiovascular, analgesic, endocrine, psychotropic, respiratory, renal, and immunomodulatory activities. Each of the more than 1000 assays comprises a detailed protocol outlining the purpose and rationale of the method, a critical assessment of the results and their pharmacological and clinical relevance. In addition, animal models of rare diseases are described.
Drug discovery and development
Presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace. It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing. This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Drug development and approval process
Drug discovery is the process of identifying and characterizing molecules with the potential to safely modulate disease, with a goal to bring medicines that can improve the lives of patients. It is a lengthy and resource intensive process, that requires close cooperation across multiple disciplines. Optimizing the process of drug discovery is of great interest to the pharmaceutical industry, as the efficient identification and selection of suitable drug candidates can have a dramatic impact on the cost and profitability of new medicines.
Drug design : A conceptual overview
The newer research areas in pharmaceutical sciences, particularly molecular modeling and simulations, prompted a more efficient drug discovery process. Informatics integrated with pharmaceutical sciences (cheminformatics and bioinformatics) became an essential component of drug research. Drug informatics such as genomics and proteomics assists in the Rational Drug Design (RDD). This emerging discipline is known as “Computer-Aided Drug Design" (CADD), which has profound application in RDD. The advanced and adequate practice in drug design informatics is essential for pharmacy graduates. Hence, a companion for acquiring knowledge on these concepts is vital. The students of B. Pharmacy, M. Pharmacy (Pharmaceutical Chemistry, Pharmacology, and Pharmaceutics), biotechnology, biomedical engineering and other interdisciplinary fields may find this book as a reference guide.
Drug delivery via nasal route
Over the past 10 years, the interest in intranasal drug delivery has increased. The objective of this research is to summarize recent developments on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, nevertheless, there are still formulation limitations and side effects to be optimized. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This research describes the anatomical, histological and physiological basis and summarizes currently approved drugs for administration via intranasal delivery. Further, the research focuses on advantages and disadvantages of intranasal applied compounds and discusses formulation aspects that need to be considered for drug development.
Drug delivery trends ; Vol. 3 : Expectations and realities of multifunctional drug delivery systems
Examines a drift in the pharmaceutical field across the wide range of dosage forms, drug delivery systems (micro and nanoparticulate), at the regulatory front and on new types of therapies in the market. This book covers the challenges on drug delivery systems in terms of preclinical and current ways of determining quality and the options to solve the challenges associated with this. Most small-medium scale industries and academics struggle with initial regulatory challenges so a detailed discussion on regulatory trend covers the necessary basic understanding of regulatory procedures and provides the required guidance.
Drug delivery technology : Herbal bioenhancers in pharmaceuticals
Bioenhancers have been used in Ayurveda historically and are now being investigated for their pharmacological effi cacy. Herbal bioenhancers work on the gastrointestinal tract to improve absorption and drug bioavailability by acting on the drug metabolic process. Many herbal drugs show low activity due to their poor lipid solubility or improper molecular size. Piperine, gingerol, naringin, quercetin, niaziridin, glycyrrhizin, allicin, curcumin, genistein and others are able to enhance the bioavailability of active pharmaceuticals. This book details various facets of herbal bio-enhancers in a single comprehensive text.
